151.00

0.15% -0.225

After Hours: 149.77 -1.225 -0.81%

Gilead Sciences Inc (GILD)

Overview News Price History Option Chain Financials Why GILD Down? Discussions Forecast Stock Split Dividend History

Gilead Sciences Inc stock is traded at $151.00, with a volume of 5.98M. It is down -0.15% in the last 24 hours and up +11.64% over the past month. Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Previous Close:

$151.22

Open:

$149.23

24h Volume:

5.98M

Relative Volume:

0.84

Market Cap:

$187.23B

Revenue:

$29.79B

Net Income/Loss:

$9.22B

P/E Ratio:

20.55

EPS:

7.3494

Net Cash Flow:

$10.23B

1W Performance:

+3.65%

1M Performance:

+11.64%

6M Performance:

+1.87%

1Y Performance:

+33.90%

1-Day Range:

$149.23

$151.19

1-Week Range:

$143.18

$152.55

52-Week Range:

$108.46

$157.29

Gilead Sciences Inc Stock (GILD) Company Profile

Name

Gilead Sciences Inc

Sector

Healthcare (1074)

Industry

Drug Manufacturers - General (20)

Phone

(650) 574-3000

Address

333 LAKESIDE DR, FOSTER CITY, CA

Employee

17,000

Twitter

@GileadSciences

Next Earnings Date

2026-10-29

Latest SEC Filings

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, MRK, NVS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GILD Gilead Sciences Inc	151.00	177.86B	29.79B	9.22B	10.23B	7.3494
LLY Lilly Eli Co	1,149.36	1.11T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	275.23	644.33B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	256.46	462.68B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	150.33	367.58B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	159.99	296.97B	54.66B	13.58B	16.05B	7.0171

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-26	Initiated	Jefferies	Buy
Feb-20-26	Initiated	Barclays	Equal Weight
Feb-11-26	Reiterated	Needham	Buy
Jan-07-26	Resumed	UBS	Buy
Nov-24-25	Resumed	Truist	Buy
Nov-13-25	Initiated	Scotiabank	Sector Outperform
Aug-19-25	Upgrade	Daiwa Securities	Neutral → Outperform
Aug-08-25	Upgrade	Truist	Hold → Buy
Jul-25-25	Upgrade	Needham	Hold → Buy
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight
Mar-04-25	Reiterated	Oppenheimer	Outperform
Feb-18-25	Upgrade	Deutsche Bank	Hold → Buy
Feb-13-25	Upgrade	DZ Bank	Hold → Buy
Jan-10-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-10-24	Resumed	BofA Securities	Buy
Nov-15-24	Initiated	Wolfe Research	Outperform
Nov-14-24	Initiated	Citigroup	Buy
Nov-08-24	Downgrade	Maxim Group	Buy → Hold
Oct-21-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-17-24	Initiated	Bernstein	Outperform
Oct-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform
May-01-24	Reiterated	Maxim Group	Buy
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold
Feb-22-24	Downgrade	Truist	Buy → Hold
Nov-09-23	Initiated	Deutsche Bank	Hold
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy
Sep-06-23	Initiated	HSBC Securities	Reduce
Jul-24-23	Reiterated	Barclays	Equal Weight
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-28-23	Resumed	Piper Sandler	Overweight
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-13-22	Resumed	BofA Securities	Neutral
Dec-09-22	Downgrade	DZ Bank	Buy → Hold
Oct-31-22	Upgrade	Barclays	Underweight → Equal Weight
Oct-28-22	Reiterated	BMO Capital Markets	Market Perform
Oct-28-22	Reiterated	Cowen	Outperform
Oct-28-22	Reiterated	JP Morgan	Overweight
Oct-28-22	Reiterated	Jefferies	Buy
Oct-28-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-28-22	Reiterated	RBC Capital Mkts	Outperform
Oct-28-22	Upgrade	Truist	Hold → Buy
Oct-28-22	Reiterated	Wells Fargo	Equal Weight
Oct-04-22	Upgrade	JP Morgan	Neutral → Overweight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
May-23-22	Initiated	SVB Leerink	Mkt Perform
Feb-28-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Feb-02-22	Reiterated	BMO Capital Markets	Outperform
Feb-02-22	Reiterated	BofA Securities	Neutral
Feb-02-22	Reiterated	RBC Capital Mkts	Outperform
Feb-02-22	Reiterated	Truist	Hold
Feb-02-22	Reiterated	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Argus	Hold → Buy
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-09-21	Resumed	Wells Fargo	Equal Weight
Dec-06-21	Initiated	Goldman	Neutral
Nov-19-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Nov-19-21	Resumed	Piper Sandler	Neutral
Oct-20-21	Resumed	Cowen	Outperform
Jul-30-21	Reiterated	BMO Capital Markets	Market Perform
Jul-30-21	Reiterated	RBC Capital Mkts	Outperform
Apr-01-21	Upgrade	Bernstein	Mkt Perform → Outperform
Mar-30-21	Upgrade	Redburn	Neutral → Buy
Jan-19-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-04-21	Upgrade	Guggenheim	Neutral → Buy
Nov-03-20	Resumed	Morgan Stanley	Equal-Weight
Oct-28-20	Initiated	UBS	Neutral
Sep-30-20	Resumed	Jefferies	Buy
Sep-15-20	Upgrade	Maxim Group	Hold → Buy
Jul-31-20	Reiterated	Credit Suisse	Neutral
Jul-31-20	Reiterated	Morgan Stanley	Equal-Weight
Jul-31-20	Reiterated	Piper Sandler	Overweight
Jul-31-20	Reiterated	RBC Capital Mkts	Outperform
Jul-31-20	Reiterated	SunTrust	Hold
Jul-31-20	Reiterated	Wells Fargo	Equal Weight
Jul-20-20	Upgrade	Credit Suisse	Underperform → Neutral
Jun-03-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
May-26-20	Upgrade	SunTrust	Sell → Hold
May-01-20	Downgrade	JP Morgan	Overweight → Neutral
May-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-01-20	Downgrade	SunTrust	Hold → Sell
Apr-27-20	Downgrade	UBS	Buy → Neutral
Apr-20-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Apr-20-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-17-20	Downgrade	CFRA	Hold → Sell

View All

Gilead Sciences Inc Stock (GILD) Latest News

01:41 AM

[Press release] FDA approves Gilead’s Bixlenvo™, a new once-daily single tablet option for virologically suppressed adults with HIV, including those on complex regimens - European AIDS Treatment Group

01:41 AM

07:51 AM

Gilead Sciences stock gains after narrowing Q2 loss and firming 2026 guidance - AD HOC NEWS

07:51 AM

06:47 AM

Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals - GlobeNewswire Inc.

06:47 AM

06:12 AM